The FDA's final guidance on Conducting Clinical Trials With Decentralized Elements (September 2024) confirms that sponsors can shift trial activities such as telehealth visits, home-based assessments, and local provider support outside the traditional site, provided participant safety, data integrity, and risk-based monitoring are built into the design. For trials with ocular endpoints, that shift only works if the decentralized model is hybrid from day one: calibrated equipment and certified ophthalmic technicians still have to travel to the participant, because BCVA, IOP, and OCT can't be captured to FDA standards through a phone camera or a wearable.
What Does the FDA's Decentralized Trials Guidance Actually Require?
The FDA's guidance doesn't create a separate regulatory pathway for decentralized trials. It clarifies how sponsors apply existing GCP standards when parts of a trial happen outside the investigational site. Three requirements matter most for ophthalmic endpoints:
- Participant safety stays with the sponsor, regardless of where an assessment happens. Delegating a visit to a mobile unit or local provider doesn't delegate accountability for adverse event capture.
- Data integrity requires the same rigor remotely as on-site. Real-time data transfer, audit trails, and standardized SOPs have to hold up across every location a participant is assessed.
- Risk-based monitoring plans need to name the decentralized elements explicitly. A generic monitoring plan written for a single-site trial won't satisfy reviewers once ocular assessments are happening at multiple points of need.
Dr. David Gibson, Chief Clinical Officer at 20/20 Onsite, put it directly: "Data integrity and patient safety are the most integral parts of a clinical trial, and they're also where decentralization is most likely to break down if it isn't built correctly. Our IT security and operations teams are structured around keeping every subject's data safe, secure, and accurate, no matter where the visit happens."
Why Do Ocular Endpoints Complicate Decentralization?
Most DCT strategies assume digital convenience can replace controlled clinical conditions. That assumption fails for ophthalmic assessments. BCVA, IOP, OCT, and fundus imaging depend on calibrated instruments and trained operators working in a standardized environment. A participant's own phone, a consumer wearable, or an uncalibrated device at a local clinic introduces variability the FDA's guidance is explicitly trying to prevent.
This is where a specialized ophthalmic execution partner matters more than a general telehealth or home-health vendor. 20/20 Onsite isn't a logistics company that happens to touch clinical trials. Our point-of-need ophthalmic clinical trial solutions exist to solve exactly this problem: bring the calibrated equipment and certified technician to the participant, so the assessment meets the same standard it would inside a traditional site.
How Should Sponsors Build FDA-Aligned Hybrid Models for Ocular Endpoints?
A compliant hybrid model must be built into the protocol from the start, not retrofitted after enrollment stalls. Sponsors should expect:
- Standardized SOPs and validated equipment applied identically across every deployment location, whether that's a mobile vision clinic, a partner site, or a participant's home.
- Documented calibration logs and training records that are traceable and audit-ready, since this is the paper trail reviewers ask for first.
- Secure, real-time data transfer with the same audit trail requirements as a fixed site, so ocular assessments and adverse events are captured accurately regardless of location.
- Third-party site-readiness validation, where available. 20/20 Onsite's teams hold the Precision Vision Site-Readiness Certification, which gives sponsors a documented, third-party benchmark that our mobile units meet standardized readiness criteria before a study ever starts.
Pamela Tomic, Clinical Trial Manager at 20/20 Onsite, noted: "The FDA guidance signals continued support for decentralized elements and lays out the practices sponsors need to address the regulatory questions that come with them. Our experience running ophthalmic assessments across a range of decentralized visit models means we're already set up for where this trend is heading."
What Does This Mean for Trial Timelines and Participant Access?
The FDA's guidance identifies equitable access as a design requirement, not a nice-to-have, particularly for sponsor-provided digital health technologies and connectivity support. For ocular endpoint trials, that access problem is largely a travel problem. Participants who can't reach a site with the right ophthalmic equipment either drop out or never enroll, and both outcomes hurt data diversity and trial timelines.
A hybrid execution model built for decentralized and virtual assessment feasibility closes that gap without asking sponsors to compromise on endpoint quality. Participants are assessed closer to home, sponsors keep the calibrated, audit-ready data reviewers expect, and enrollment isn't limited to whoever happens to live near a site equipped for ophthalmic testing.
If you're planning a trial with ocular endpoints and want to confirm that your decentralized model holds up against the FDA's current guidance, request a protocol review with our team.
Frequently Asked Questions
What is a decentralized clinical trial (DCT) under FDA guidance? The FDA defines a DCT as a trial in which some or all trial-related activities occur at locations other than the traditional investigational site. That can include telehealth visits, home-based assessments, support from local healthcare providers, or mobile research units, used alone or in combination with standard site visits.
Does FDA guidance allow local providers to collect ocular endpoint data? Yes, with conditions. The FDA permits qualified local providers to perform specific trial tasks, but the sponsor remains responsible for ensuring that those providers are trained, that the equipment is calibrated to protocol standards, and that the data meet the same integrity requirements as a site-collected assessment.
How does risk-based monitoring apply to ocular assessments in decentralized trials? Risk-based monitoring plans need to explicitly account for each decentralized element in the protocol. For ocular endpoints, this typically means documenting equipment calibration schedules, technician certification, and the data transfer and audit-trail process for every deployment location.
Can ocular endpoints be captured through a fully virtual trial model? Rarely to the standard the FDA expects. BCVA, IOP, and OCT require calibrated instruments and trained operators in a controlled environment. Most sponsors running ocular endpoint studies need a hybrid model that brings certified staff and validated equipment to the participant, rather than relying on remote self-assessment tools alone.
What certifications indicate a site or mobile unit is ready for decentralized ophthalmic assessments? Third-party site-readiness certifications, such as the Precision Vision Site-Readiness Certification, give sponsors documented proof that a deployment location meets standardized calibration, staffing, and protocol-readiness criteria before enrollment begins.
How does 20/20 Onsite support FDA-aligned hybrid trial models? 20/20 Onsite provides point-of-need ophthalmic clinical trial solutions, including Mobile Vision Clinics staffed by certified technicians using validated, calibrated equipment. Our teams follow the same standardized SOPs and data integrity protocols regardless of deployment location, aligning directly with the FDA's decentralized trials guidance.
What's the difference between a hybrid and a fully remote decentralized trial? A fully remote model aims to conduct all trial activities off-site, typically via digital tools and self-reported data. A hybrid model combines remote or point-of-need elements, such as mobile ophthalmic assessments, with select in-person visits. For ocular endpoints, the hybrid model is almost always the only one that meets FDA data-quality expectations.